Alaunos Therapeutics (TCRT) Depreciation & Amortization (CF) (2009 - 2026)

Alaunos Therapeutics has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $8000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) changed N/A year-over-year to $8000.0; the trailing twelve-month figure through Mar 2026 stood at $15000.0 (changed N/A YoY), and the FY2025 full-year result was $7000.0, up 250.0% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $8000.0, up from $7000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $699000.0 in Q2 2023, with the low at -$1000.0 in Q4 2024.
• Historically, Depreciation & Amortization (CF) has averaged $390461.5 across 5 years, with a median of $679000.0 in 2023.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) sank 100.44% — and 2025, when it surged 800.0%.
• Alaunos Therapeutics' Depreciation & Amortization (CF) stood at $694000.0 in 2022, then plunged by 67.44% to $226000.0 in 2023, then plunged by 100.44% to -$1000.0 in 2024, then surged by 800.0% to $7000.0 in 2025, then increased by 14.29% to $8000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $8000.0 (Q1 2026), $7000.0 (Q4 2025), and -$1000.0 (Q4 2024), per Business Quant data.